

Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from January 2016

For further details see *PACE Bulletin* Volume 10; Number 2 (January 2016)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Daclatasvir 30mg and 60mg tablets (Daklinza) (Bristol-Myers Squibb Pharmaceuticals Ltd)	For use in combination with other medicines for the treatment of chronic hepatitis C virus infection in adults	RED Approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Idelalisib 100mg and 150mg tablets (Zydelig) (Gilead Sciences Ltd)	For untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation or for chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months.	RED Approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Insulin glargine 300units/ml injection (Toujeo) (Sanofi)	Treatment of diabetes mellitus in adults.	AMBER without shared care Approved for inclusion in the Lincolnshire Joint Formulary. Should only be initiated on the advice of a diabetologist or a GP with a specialist interest in diabetes for those experiencing an unacceptable frequency and/or severity of nocturnal hypoglycaemia or attempting to achieve better hypoglycaemia control during treatment with established insulins
Ledipasvir 90mg/ sofosbuvir 400mg tablets (Harvoni) (Gilead Sciences)	For the treatment of chronic hepatitis C (CHC) in adults	RED Approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Levonorgestrel 13.5mg T-shaped intrauterine system (<i>Jaydess</i>) (Bayer)	Contraception	Changed from RED to GREEN. Second line for women requiring a shorter duration of contraception and/or a smaller device.
<i>Levonorgestrel 52mg T-shaped intrauterine system (Levosert)</i> (Actavis)	Contraception Idiopathic menorrhagia.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Levonorgestrel 52mg T-shaped intrauterine system (<i>Mirena</i>) (Bayer)	Contraception. Idiopathic menorrhagia. Protection from endometrial hyperplasia during oestrogen replacement therapy.	GREEN – first line Available through the <i>Lincolnshire Joint Formulary</i> .
Ombitasvir 12.5mg/ paritaprevir 75mg/ ritonavir 50mg tablets (<i>Viekirax</i>) (AbbVie Ltd)	For use in combination with other medicines for the treatment of chronic hepatitis C in adults	RED Approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Oxycodone sustained release tablets 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg and 80mg (Abtard) (DB Ashbourne Ltd)	Severe pain that can only be adequately managed with opioid analgesics	GREEN Approved for use through the Lincolnshire Joint Formulary. Prescribe by brand.

Oxycodone sustained release tablets 5mg, 10mg, 15mg, 20mg, 40mg, 80mg and 120mg (Longtec) (Qdem Pharmaceuticals Ltd)	Moderate to severe cancer pain or post-op pain. Severe pain requiring a strong opioid.	GREEN Approved for use through the Lincolnshire Joint Formulary. Prescribe by brand.
Oxycodone sustained release tablets 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg and 80mg (Oxeltra) (Wockhardt UK Ltd)	Moderate to severe cancer pain or post-op pain. Severe pain requiring a strong opioid.	RED-RED Not approved for use through the Lincolnshire Joint Formulary. Should not be prescribed.
Oxycodone sustained release tablets 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg and 120mg (OxyContin) (Napp Pharmaceuticals Ltd)	Moderate to severe cancer pain or post-op pain. Severe pain requiring a strong opioid.	RED-RED Not approved for use through the Lincolnshire Joint Formulary. Should not be prescribed.
Oxycodone sustained release tablets 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg and 80mg (Reltebon) (Actavis UK Ltd)	Severe pain requiring an opioid analgesic.	GREEN Approved for use through the Lincolnshire Joint Formulary. Prescribe by brand.
Paclitaxel 100mg and 250mg infusion (Abraxane) (Celgene Ltd)	For use in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. For the treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy is not appropriate	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary. RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Pembrolizumab 50mg powder for infusion (Keytruda) (Merck Sharp & Dohme Limited)	For the treatment of advanced (unresectable or metastatic) melanoma in adults.	RED Approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Simeprevir 150mg capsules (Olysio) (Janssen Cilag Ltd)	For use in combination with sofosbuvir for the urgent treatment of chronic hepatitis C infection of genotype 1 or 4 when peg interferon alfa cannot be used because of intolerance or contr-indications.	RED-RED Not approved for use through the Lincolnshire Joint Formulary for this indication.
Tolvaptan tablets 15mg, 30mg, 45mg and 60mg (Jinarc) (Otsuka)	To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease in adults with CKD stage 1 to 3 with evidence of rapidly progressing disease	RED Approved for inclusion in the Lincolnshire Joint Formulary for this indication; it should be prescribed by brand to avoid confusion with an alternative tolvaptan formulation (Samsca) licensed for an alternative indication and not approved for use through the Formulary .

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

<p>THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION</p>
--